AZACITIDINE in Danish translation

• azacitidin
• azacitidingruppen

Examples of using Azacitidine in English and their translations into Danish

One case of overdose with azacitidine was reported during clinical trials.
Der blev rapporteret ét tilfælde af overdosering med azacitidin under de kliniske studier.

No formal clinical drug interaction studies with azacitidine have been conducted.
Der er ikke foretaget nogen officiel klinisk undersøgelse af lægemiddelinteraktion med azacitidin.

Pregnancy There are no adequate data on the use of azacitidine in pregnant women.
Graviditet Foreliggende data for anvendelse af azacitidin til gravide er utilstrækkelige.

AZA azacitidine; CCR conventional care regimens;
AZA azacitidin; CCR konventionelle behandlingsregimer(conventional care regimens);

The active substance in Vidaza, azacitidine, is a medicine belongs to the group‘ anti-metabolites.
Det aktive stof i Vidaza, azacitidin, er et middel, som tilhører gruppen"antimetabolitter.

Azacitidine plus best supportive care(BSC)(n 179) was compared to conventional care regimens CCR.
Azacitidin plus"bedste understøttende behandling"("best supportive care", BSC)(n 179) blev sammenlignet med konventionelle behandlingsregimer"Conventional Care Regimens", CCR.

permanent discontinuation of azacitidine, or reduction of azacitidine dose in the pivotal study.
bivirkninger til midlertidig seponering, permanent seponering eller dosisreduktion af azacitidin.

If reconst ituted azacitidine comes into contact with the skin, immediately and thoroughly wash with soap and water.
Skyl øjeblikkeligt og grundigt med sæbe og vand, hvis rekonstitueret azacitidin kommer i kontakt med huden.

Azacitidine induced tumours of the haematopoietic system in female mice,
Azacitidin inducerede tumorer i det hæmatopoietiske system hos hunmus,

The table below contains the adverse reactions for which a causal relationship with azacitidine treatment could reasonably be established.
Nedenstående tabel indeholder de bivirkninger, for hvilke et kausalt forhold til behandlingen med azacitidin anses for sandsynligt.

Excretion Azacitidine is cleared rapidly from plasma with a mean elimination half-life(t½) after subcutaneous administration of 41± 8 minutes.
Udskillelse Azacitidin udskilles hurtigt fra plasma med en gennemsnitlig elimineringshalveringstid(t½) efter subkutan administration på 41 ± 8 minutter.

Vidaza should not be used in people who may be hypersensitive(allergic) to azacitidine or any of the other ingredients.
Vidaza bør ikke anvendes hos patienter, der kan være overfølsomme(allergiske) over for azacitidin eller andre af indholdsstofferne.

Azacitidine is an analogue of cytidine,
Azacitidin er en cytidinanalog,

Absorption Azacitidine was rapidly absorbed after subcutaneous administration with peak plasma azacitidine concentrations of 750± 403 ng/ ml occurring at 0.5 h(the first sampling point) after dosing.
Absorption Azacitidin blev hurtigt absorberet efter subkutan administration med peak- plasma- azacitidinkoncentrationer på 750 ± 403 ng/ ml ved 0, 5 t(det første prøvetagningstidspunkt) efter dosering.

After reconstitution with 4 ml of water for injections, the reconstituted suspension contains 25 mg/ml azacitidine.• The other ingredient is mannitol E421.
Efter opblanding med 4 ml vand til injektionsvæske indeholder den opblandede suspension 25 mg/ ml azacitidin.• Øvrige indholdsstoffer: mannitol E421.

skin was seen in mice treated with azacitidine administered intraperitoneally for 50 weeks.
hud hos mus, der blev behandlet med azacitidin, administreret intraperitonealt i 50 uger.

Mechanism of action Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA.
Virkningsmekanisme Det vurderes, at Azacitidin udøver sine antineoplastiske virkninger ved flere mekanismer, herunder cytotoksicitet på abnorme hæmatopoietiske celler i knoglemarven og hypometylering af DNA.

Administration of azacitidine to male mice prior to mating with untreated female mice resulted in decreased fertility
Administration af azacitidin til hanmus inden parring med ubehandlede hunmus resulterede i nedsat fertilitet og tab af afkom

death were reported rarely in patients treated with intravenous azacitidine in combination with other chemotherapeutic agents.
død, er blevet rapporteret i sjældne tilfælde hos patienter i kombinationsbehandling med intravenøs azacitidin og andre kemoterapeutika.

The most commonly reported adverse reactions with azacitidine treatment were haematological reactions(71.4%)
De oftest rapporterede bivirkninger ved behandlingen med azacitidin var hæmatologiske(71, 4%), herunder trombocytopeni,